Spatial Proximity of LAG-3 and T Cell Receptor: A New Paradigm for T Cell Suppression

References

[1] J. Du, H. Chen, J. You, et al., “Proximity Between LAG-3 and the T Cell Receptor Guides Suppression of T Cell Activation and Autoimmunity,” Cell 188, no. 15 (2025): 4025–4042.e20.

[2] L. P. Andrews, A. E. Marciscano, C. G. Drake, and D. A. Vignali, “LAG3 (CD223) as a Cancer Immunotherapy Target,” Immunological Reviews 276, no. 1 (2017): 80–96.

[3] T. Maruhashi, I. M. Okazaki, D. Sugiura, et al., “LAG-3 Inhibits the Activation of CD4(+) T Cells That Recognize Stable pMHCII Through Its Conformation-dependent Recognition of pMHCII,” Nature Immunology 19, no. 12 (2018): 1415–1426.

[4] Z. Wang, M. Yin, G. Lou, et al., “Targeting LAG-3 Restores CD8⁺ T Cell Effector Function Through CD94/NKG2-Qa-1b Signaling,” MedComm-Oncology 3, no. 4 (2024): e70003.

[5] Y. Jiang, A. Dai, Y. Huang, et al., “Ligand-induced Ubiquitination Unleashes LAG3 Immune Checkpoint Function by Hindering Membrane Sequestration of Signaling Motifs,” Cell 188, no. 9 (2025): 2354–2371.e18.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.